BTTC11-01: Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas

7322-CTO
Cancer - Brain
Principal Investigator: Tobias Walbert, MD

The goal of this clinical research study is to learn if an antiepileptic (anti-seizure) treatment will prevent seizures in patients with brain tumors who have not yet had a seizure. Anti-seizure drugs are designed to decrease abnormal electrical activity in the brain that plays a role in developing seizures.

In this study, lacosamide will be used as an anti-seizure medication. Lacosamide will be compared to a placebo.

A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

  1. Patients must be 18 years or older.
  2. Patients with histologically confirmed supratentorial high-grade glioma will be eligible for this protocol.
  3. All patients must sign an informed consent indicating that they are aware of the investigational nature of this study.

Please contact us for full eligibility criteria.

Open
Tiffany Pearce
(313) 916-1784